

AMICUS THERAPEUTICS INC
Form 4
June 07, 2007

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
CHL Medical Partners II Side Fund,
L.P.

(Last) (First) (Middle)

C/O GREGORY M.
WEINHOFF, 1055 WASHINGTON
BLVD.

(Street)

STAMFORD, CT 06901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS INC
[FOLD]

3. Date of Earliest Transaction
(Month/Day/Year)
06/05/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director 10% Owner
____ Officer (give title below) ____ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2007		C		1,850,540	A	(1) 1,975,456
Common Stock	06/05/2007		C		124,683	A	(1) 2,108,555

By CHL Medical Partners II, L.P. (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form

SEC 1474 (9-02)

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
					V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Series A Convertible Preferred Stock	(1)	06/05/2007		C		83,278	04/15/2002	(1)	Common Stock	83,278
Series A Convertible Preferred Stock	(1)	06/05/2007		C		5,611	04/15/2002	(1)	Common Stock	5,611
Series B Convertible Preferred Stock	(1)	06/05/2007		C		734,803	05/04/2004	(1)	Common Stock	734,803
Series B Convertible Preferred Stock	(1)	06/05/2007		C		49,509	05/04/2004	(1)	Common Stock	49,509
Series B Convertible Preferred Stock	(1)	06/05/2007		C		11,182	04/18/2006	(1)	Common Stock	11,182
Series B Convertible Preferred Stock	(1)	06/05/2007		C		753	04/18/2006	(1)	Common Stock	753
Series C Convertible Preferred Stock	(1)	06/05/2007		C		247,850	08/16/2005	(1)	Common Stock	247,850

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

Series C Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	16,669	08/16/2005	<u>(1)</u>	Common Stock	16,699
Series C Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	247,850	04/17/2006	<u>(1)</u>	Common Stock	247,850
Series C Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	16,669	04/17/2006	<u>(1)</u>	Common Stock	16,699
Series D Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	96,233	09/13/2006	<u>(1)</u>	Common Stock	96,233
Series D Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	6,484	09/13/2006	<u>(1)</u>	Common Stock	6,484
Series D Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	96,223	03/09/2007	<u>(1)</u>	Common Stock	96,233
Series D Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	6,484	03/09/2007	<u>(1)</u>	Common Stock	6,484
Series A Convertible Preferred Stock	<u>(1)</u>	06/05/2007	C	333,111	07/15/2002	<u>(1)</u>	Common Stock	333,111
Series A Convertible Preferred Stock	\$ 0 <u>(1)</u>	06/05/2007	C	22,444	07/15/2002	<u>(1)</u>	Common Stock	22,444

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

CHL Medical Partners II Side Fund, L.P.
C/O GREGORY M. WEINHOFF
1055 WASHINGTON BLVD.
STAMFORD, CT 06901

X

Signatures

CHL Medical Partners II Side Fund, L.P., By: Collinson, Howe & Lennox II, LLC, its
General Partner, By: /s/ Gregory M. Weinhoff

06/06/2007

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Each of the Series A Convertible Preferred Stock, the Series B Convertible Preferred Stock, the Series C Convertible Preferred Stock and
(1) the Series D Convertible Preferred Stock automatically converted into Amicus Therapeutics, Inc. common stock on a one-for-one basis
upon the closing of Amicus Therapeutics, Inc.'s initial public offering on June 5, 2007

These shares are owned by CHL Medical Partners II, L.P., which is under common control with CHL Medical Partners II Side Fund,
L.P. Collinson, Howe & Lennox II, LLC serves as the sole general partner of CHL Medical Partners II Side Fund, L.P. and CHL Medical
(2) Partners II, L.P. and is the indirect beneficial owner of the shares. CHL Medical Partners II Side Fund, L.P. disclaims beneficial ownership
of such shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an
admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays
a currently valid OMB number.